SSTR antagonist [68Ga]Ga-DOTA-LM3 differentiates intrapancreatic accessory spleen from neuroendocrine tumor in a patient presenting indeterminate MRI and SSTR agonist [68Ga]Ga-DOTATATE-Reference-Cited by-同舟云学术

SSTR antagonist [68Ga]Ga-DOTA-LM3 differentiates intrapancreatic accessory spleen from neuroendocrine tumor in a patient presenting indeterminate MRI and SSTR agonist [68Ga]Ga-DOTATATE

Published:2023-09-16 Issue:2 Volume:51 Page:606-608
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Xu Weizhi,Cai Jiayu,Meng Tinghua,Pang YiZhen,Chen Haojun^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00259-023-06428-5.pdf

Reference5 articles.

1. Bostanci EB, Oter V, Okten S, Kucuk NO, Soydal C, Turhan N, et al. Intra-pancreatic accessory spleen mimicking pancreatic neuroendocrine tumor on 68-Ga-dotatate PET/CT. Arch Iran Med. 2016;19:816–9.

2. Guo W, Chen Y, He X, Fu H, Huang J, Chen H. [(68) Ga]Ga-DOTATATE PET/CT versus [(68) Ga]Ga-exendin-4 PET/CT in the evaluation of metastatic insulinoma. Eur J Nucl Med Mol Imaging. 2023;50:2910–1. https://doi.org/10.1007/s00259-023-06182-8.

3. Pang Y, Meng T, Shang Q, Chen Z, Chen H. 68Ga-Exendin-4 PET/CT differentiates insulinoma from accessory spleen in a patient presenting indeterminate MRI and 68Ga-DOTATATE PET/CT findings. Clin Nucl Med. 2022;47:265–7. https://doi.org/10.1097/RLU.0000000000003895.

4. Zhu W, Cheng Y, Jia R, Zhao H, Bai C, Xu J, et al. A prospective, randomized, double-blind study to evaluate the safety, biodistribution, and dosimetry of (68)Ga-NODAGA-LM3 and (68)Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2021;62:1398–405. https://doi.org/10.2967/jnumed.120.253096.

5. Zhu W, Jia R, Yang Q, Cheng Y, Zhao H, Bai C, et al. A prospective randomized, double-blind study to evaluate the diagnostic efficacy of (68)Ga-NODAGA-LM3 and (68)Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with (68)Ga-DOTATATE. Eur J Nucl Med Mol Imaging. 2022;49:1613–22. https://doi.org/10.1007/s00259-021-05512-y.